← SynDRA
TALAZOPARIB
SynDRA canonical compound SYN0037852 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | PARP1 |
|---|
| Mechanism of action | PARP inhibitor |
|---|
| Indication | breast cancer |
|---|
| Disease area | oncology |
|---|
All known targets
- PARP1
- PARP2
- PARP10
- PARP16
- PARP3
- PARP4
- TNKS
Mechanisms of action (all sources)
- PARP inhibitor
- PARP2 INHIBITOR
- Poly [ADP-ribose] polymerase 2 inhibitor
- PARP1 INHIBITOR
- Poly [ADP-ribose] polymerase-1 inhibitor
Drug classes
- Antineoplastic Agents
- Enzyme Inhibitors
- Poly(ADP-ribose) Polymerase Inhibitors
- Poly(ADP-Ribose) Polymerase Inhibitors
- Poly(ADP-Ribose) Polymerase Inhibitor
ATC classes
- L01X · OTHER ANTINEOPLASTIC AGENTS
Cross-references
Synonyms
- talazoparib tosylate
- talzenna
- BMN-673
- BMN-673ts
- LT 006673
- LT-00673
- LT-673
- MDV-3800
- PF-06944076
- TALAZOPARIB (BMN 673)
- Talazoparib tosylate
- Talazoparib (BMN 673)
- UNII-9QHX048FRV
- 9QHX048FRV
- Talazoparib [USAN:INN]
- Talzenna
- 4pjt
- 2YQ
- BMN 673
- Talazoparib (BMN-673)
- BMN673
- (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one
- Talazoparib(BMN-673)
- (8s,9r)-5-Fluoro-8-(4-Fluorophenyl)-9-(1-Methyl-1h-1,2,4-Triazol-5-Yl)-2,7,8,9-Tetrahydro-3h-Pyrido[4,3,2-De]phthalazin-3-One
- 3H-Pyrido(4,3,2-de)phthalazin-3-one, 5-fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-, (8S,9R)-
- (11S,12R)-7-fluoro-11-(4-fluorophenyl)-12-(2-methyl-1,2,4-triazol-3-yl)-2,3,10-triazatricyclo[7.3.1.05,13]trideca-1,5(13),6,8-tetraen-4-one
- TALAZOPARIB [MI]
- TALAZOPARIB [INN]
- Talazoparib (USAN/INN)
- TALAZOPARIB [USAN]
- TALAZOPARIB [WHO-DD]
- (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-3H-pyrido[4,3,2-de]phthalazine-3-one
- GTPL8313
- SCHEMBL2299348
- CHEMBL3137320
- BMN673,BMN-673
- DTXSID001025928
- AMY27900
Reported adverse events
- Alopecia
- Dizziness
- Dysgeusia
- Fatigue
- Headache
- Myelosuppression
- Nausea
- Vomiting
- Decreased appetite
- Alanine aminotransferase increased
- Fracture
- Aspartate aminotransferase increased
Look up TALAZOPARIB in the interactive SynDRA portal →